Equillium: Oppenheimer sets a $7 price target and emphasizes the potential for EQ504 in a $12 billion market!
Reading Time: 3 minutes
Equillium Inc. (EQ) positions itself as an innovative player in the field of immunobiology, focusing heavily on the development of therapies for severe autoimmune and inflammatory diseases with high unmet medical needs. From the management's perspective, the drug candidate EQ504 is currently the absolute focal point, a potent and selective aryl hydrocarbon receptor (AhR) modulator. Just recently, in April, the company was able to present promising preclinical data at the IMMUNOLOGY2026 conference in Boston, demonstrating that EQ504 not only inhibits...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
